Literature DB >> 891097

Effect of pentobarbital on the disposition of alprenolol.

G Alván, K Piafsky, M Lind, C von Bahr.   

Abstract

Alprenolol was administered orally and intravenously to 5 healthy subjects before and after 10 to 14 daily doses of 0.1 gm pentobarbital. The area under the plasma concentration time curve after an oral 200-mg dose decreased from 706 +/- 277 to 154 +/- 48 ng/ml-hr (mean and SD) with the barbiturate treatment, but there was no significant change in elimination rate. The change in area corresponded to an increase in extraction by the liver from 0.72 +/- 0.13 to 0.93 +/- 0.01. The disposition of a 5.0-mg intravenous dose of alprenolol did not change significantly after pentobarbital treatment. There was no indication of a marked change in hepatic blood flow estimated from the clearance of alprenolol after intravenous administration. It is concluded that pentobarbital administration induces the metabolism of alprenolol in man and that the pharmacokinetic theories derived for hepatic extraction of drugs subject to a high metabolic clearance can be successfully applied.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 891097     DOI: 10.1002/cpt1977223316

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  19 in total

Review 1.  Individual differences in the disposition of drugs metabolised in the body.

Authors:  G Alvan
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

2.  Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.

Authors:  P Seideman; K O Borg; K Haglund; C Von Bahr
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

3.  Differential effects of enzyme induction on antipyrine metabolite formation.

Authors:  M Danhof; R M Verbeek; C J van Boxtel; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

4.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

5.  Multidose studies in the human metabolism of pentobarbitone.

Authors:  W C Baldeo; J N Gilbert; J W Powell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1980       Impact factor: 2.441

Review 6.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 7.  Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.

Authors:  G Heinemeyer
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

8.  Prediction of metabolic drug interactions involving beta-adrenoceptor blocking drugs.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

9.  Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs.

Authors:  E Perucca; A Richens
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

10.  Oxazepam pharmacokinetics in patients with epilepsy treated long-term with phenytoin alone or in combination with phenobarbitone.

Authors:  A K Scott; A S Khir; W H Steele; G M Hawksworth; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.